| Title |
Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States
|
|---|---|
| Published in |
PharmacoEconomics, August 2013
|
| DOI | 10.1007/s40273-013-0078-x |
| Pubmed ID | |
| Authors |
Reginald Villacorta, Joel W. Hay, Andrew Messali |
| Abstract |
Limited information is available on the cost effectiveness of ustekinumab and alternative biologic treatments in a United States (US) setting. Given the recent head-to-head clinical trial study of ustekinumab and etanercept, an economic model comparing the two treatments can be constructed. Etanercept and ustekinumab are indicated for the treatment of chronic moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 1% |
| Unknown | 69 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 19% |
| Researcher | 11 | 16% |
| Student > Ph. D. Student | 7 | 10% |
| Student > Postgraduate | 6 | 9% |
| Other | 5 | 7% |
| Other | 11 | 16% |
| Unknown | 17 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 39% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
| Economics, Econometrics and Finance | 5 | 7% |
| Business, Management and Accounting | 4 | 6% |
| Psychology | 2 | 3% |
| Other | 6 | 9% |
| Unknown | 19 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 June 2019.
All research outputs
#2,926,577
of 22,719,618 outputs
Outputs from PharmacoEconomics
#266
of 1,814 outputs
Outputs of similar age
#26,725
of 199,028 outputs
Outputs of similar age from PharmacoEconomics
#3
of 12 outputs
Altmetric has tracked 22,719,618 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,814 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,028 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.